Foghorn Therapeutics Inc. (FHTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Foghorn Therapeutics Inc. on January 23, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Cambridge, MA. Its common stock trades on The Nasdaq Global Market under the symbol "FHTX".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance matters.
Material Changes
On January 23, 2025, the Company received a notice from Nasdaq stating it no longer complies with Nasdaq Listing Rule 5605 regarding audit committee requirements. The non-compliance stems from the resignation of Adam M. Koppel, M.D., Ph.D., from the Board and Audit Committee effective December 29, 2024. Consequently, the Audit Committee currently consists of only two qualified directors, whereas the rule requires at least three.
Outlook, Risks, and Management Commentary
- Cure Period: Nasdaq has granted a cure period to regain compliance. This period expires on the earlier of the Company's next annual shareholders meeting or December 29, 2025. If the next annual meeting occurs before June 27, 2025, compliance must be evidenced by June 27, 2025.
- Management Plan: The Board intends to appoint a new or existing independent Board member to the Audit Committee to restore the required three-member composition.
- Risk: Failure to regain compliance within the cure period could result in delisting from The Nasdaq Global Market.
Key Facts for Investor Verification
- Verify the timeline for the appointment of a new Audit Committee member to ensure compliance before the cure period deadline.
- Monitor the date of the next annual shareholders meeting to determine the specific expiration date of the cure period.
- Review the Company's subsequent filings for confirmation of the new Audit Committee composition.